Market Checkup: Spotlight on AbbVie
In this edition of The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso take a close look at AbbVie, the pharmaceutical company that was spun out of Abbott at the start of the year.
One of the best parts of owning big pharma stocks like AbbVie is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Market Checkup: Spotlight on AbbVie originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences and Celgene. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.